Trials / Completed
CompletedNCT04834856
Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients
A Phase 2a Open Label, Non-comparative, Single Dose Escalation Study to Evaluate the Dynamics of Viral Clearance, Pharmacokinetics and Tolerability of Ensovibep in Patients With Symptomatic COVID-19 Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Molecular Partners AG · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will investigate how ensovibep is distributed throughout the body, the viral clearance and the tolerability of ensovibep in patients with symptomatic COVID-19 disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ensovibep | The study will start with a low-dose cohort and after a safety review escalate to the higher dose cohort. One administration at day 1 by infusion. |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2021-08-20
- Completion
- 2021-08-20
- First posted
- 2021-04-08
- Last updated
- 2021-09-08
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT04834856. Inclusion in this directory is not an endorsement.